2021
Clinical trial transparency and data sharing among biopharmaceutical companies and the role of company size, location and product type: a cross-sectional descriptive analysis
Axson S, Mello MM, Lincow D, Yang C, Gross C, Ross JS, Miller J. Clinical trial transparency and data sharing among biopharmaceutical companies and the role of company size, location and product type: a cross-sectional descriptive analysis. BMJ Open 2021, 11: e053248. PMID: 34281933, PMCID: PMC8291313, DOI: 10.1136/bmjopen-2021-053248.Peer-Reviewed Original Research
2018
Disparities in the Use of Programmed Death 1 Immune Checkpoint Inhibitors
O'Connor JM, Seidl‐Rathkopf K, Torres AZ, You P, Carson KR, Ross JS, Gross CP. Disparities in the Use of Programmed Death 1 Immune Checkpoint Inhibitors. The Oncologist 2018, 23: 1388-1390. PMID: 30012876, PMCID: PMC6291337, DOI: 10.1634/theoncologist.2017-0673.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAnti-PD1 agentsAnti-PD1 treatmentImmune checkpoint inhibitorsCheckpoint inhibitorsDeath-1 immune checkpoint inhibitorPrior anticancer therapyDeath protein 1Cell lung cancerCommunity-based cohortAdvanced-stage cancerRenal cell carcinomaSex-based disparitiesSystemic treatmentCell carcinomaLung cancerMultivariable modelObservational studyHigher oddsStage cancerRace-based disparitiesPatient careAnticancer therapyProtein 1Patients
2016
Commentary: Diagnostic devices in clinical trials have high stakes for patient care
Rathi VK, Krumholz HM, Ross JS. Commentary: Diagnostic devices in clinical trials have high stakes for patient care. The BMJ 2016, 354: i5197. PMID: 27681285, DOI: 10.1136/bmj.i5197.Commentaries, Editorials and Letters